JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 243 filers reported holding JUNO THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is 0.72 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $2,615,000 | +5.0% | 57,209 | +3.1% | 0.01% | 0.0% |
| Q3 2017 | $2,490,000 | -26.1% | 55,495 | -50.7% | 0.01% | +44.4% |
| Q2 2017 | $3,368,000 | +480.7% | 112,652 | +330.7% | 0.01% | +200.0% |
| Q1 2017 | $580,000 | -3.8% | 26,156 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $603,000 | -21.6% | 26,156 | +2.1% | 0.00% | -40.0% |
| Q3 2016 | $769,000 | -12.1% | 25,618 | +12.6% | 0.01% | -16.7% |
| Q2 2016 | $875,000 | +553.0% | 22,754 | +546.8% | 0.01% | +500.0% |
| Q1 2016 | $134,000 | +7.2% | 3,518 | +23.4% | 0.00% | 0.0% |
| Q4 2015 | $125,000 | -17.8% | 2,850 | -23.7% | 0.00% | 0.0% |
| Q3 2015 | $152,000 | -19.1% | 3,733 | +6.0% | 0.00% | 0.0% |
| Q2 2015 | $188,000 | +16.0% | 3,521 | +32.2% | 0.00% | 0.0% |
| Q1 2015 | $162,000 | – | 2,663 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 1,864,174 | $85,211,000 | 94.86% |
| Crestline Management, LP | 7,631,631 | $348,841,000 | 35.74% |
| Omega Fund Management, LLC | 753,564 | $34,445,000 | 24.90% |
| DDD Partners, LLC | 191,458 | $8,752,000 | 3.40% |
| SIB LLC | 100,000 | $4,571,000 | 3.28% |
| PECONIC PARTNERS LLC | 433,587 | $19,819,000 | 2.85% |
| Cormorant Asset Management, LP | 550,000 | $25,141,000 | 2.63% |
| ARK Investment Management | 682,495 | $31,197,000 | 2.48% |
| BB BIOTECH AG | 1,925,000 | $87,992,000 | 2.48% |
| Clarius Group, LLC | 120,988 | $5,530,000 | 2.47% |